

2023 Current Fiscal Year Report: National Cancer Advisory Board

Report Run Date: 03/28/2024 08:30:55 AM

1. Department or Agency

Department of Health and Human
Services

2. Fiscal Year

2023

3. Committee or Subcommittee

National Cancer Advisory Board

3b. GSA Committee

No.

960

4. Is this New During Fiscal Year?

5. Current Charter

6. Expected Renewal Date

7. Expected Term Date

No 05/31/2022 05/31/2024

8a. Was Terminated During Fiscal Year?

No

8b. Specific Termination Authority

8c. Actual Term Date

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority

Statutory (Congress Created)

12. Specific Establishment Authority

42 U.S.C. 284a

13. Effective Date

11/20/1985

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Other Committee

16a. Total Number of Reports

1

16b. Report

Date

Report Title

REPORT FROM THE ad hoc
WORKING GROUP ON
STRATEGIC APPROACHES AND

12/07/2022 OPPORTUNITIES FOR RESEARCH
ON CANCER AMONG RACIAL AND
ETHNIC MINORITIES AND
UNDERSERVED POPULATIONS

Number of Committee Reports Listed: 1

17a. 1 **17b. Closed** 0 **17c. Partially Closed** 5 **Other Activities** 0 **17d. Total** 6
Open

Meetings and Dates

Purpose	Start	End
Program Advisory/Second Level Peer Review	12/05/2022	12/07/2022
Program Advisory/Second Level Peer Review	02/09/2023	02/09/2023
Program Advisory/Second Level Peer Review	03/27/2023	03/27/2023
Program Advisory	05/10/2023	05/10/2023
Program Advisory/Second Level Peer Review	06/13/2023	06/15/2023
Program Advisory/Second Level Peer Review	09/06/2023	09/06/2023

Number of Committee Meetings Listed: 6

	Current FY	Next FY
18a(1). Personnel		
Pmts to Non-Federal Members	\$57,200.00	\$57,200.00
18a(2). Personnel		
Pmts to Federal Members	\$15,475.00	\$15,475.00
18a(3). Personnel		
Pmts to Federal Staff	\$119,020.00	\$125,209.00
18a(4). Personnel		
Pmts to Non-Member Consultants	\$3,000.00	\$3,000.00
18b(1). Travel and Per Diem to Non-Federal Members	\$13,559.00	\$42,284.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$8,792.00	\$20,369.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$69,065.00	\$69,755.00

18d. Total	\$286,111.00	\$333,292.00
19. Federal Staff	0.60	0.60
Support Years (FTE)		

20a. How does the Committee accomplish its purpose?

The National Cancer Advisory Board (NCAB), composed of both scientific and public members, provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed \$50,000; advises on policy development, program implementation and evaluation; and research needs of the National Cancer Institute (NCI). In FY 2023, the NCAB reviewed 13,560 NCI applications requesting \$5,340,328,772 and 7 FDA SBIR applications requesting \$1,312,236. During the year, the NCAB was presented reports on various topics related to cancer research in general. Board discussions and reports included a wide variety of topics including the NCI's Childhood Cancer Data Initiative; Status of the Advance Research Projects Agency for Health (ARPA-H); Future Directions for the Division of Cancer Control and Population Sciences; Multiple Myeloma and Disparities; Adapting NCI's Clinical Trials System to a Changed Clinical Research Environment; National Cancer Plan; Cancer Research Collaborations with the European Union; Progress in Targeting KRAS through the Frederick RAS Initiative; Budget Overview; and Collaborative Approaches to Accelerate Better Therapies for Patients with Rare Tumors. NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittees on Global Cancer Research and Population Sciences, Epidemiology, and Disparities. They also provided insights regarding reports from the NCAB Subcommittees

on Planning and Budget and Clinical Investigations. At the Joint Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism, National Advisory Council on Drug Abuse and NCAB met to hear reports regarding the Adolescent Brain and Cognitive Development (ABCD) Study; Decoding Bidirectional Interactions Between Alcohol and Pain; ARPA-H; and updates from the NCI, NIAAA, and NIDA regarding efforts associated with the Collaborative Research on Addiction at NIH (CRAN) initiative. Lastly, NCAB meeting minutes for the following meetings, i.e., the August 2022 virtual meeting, December 2022 Joint NCI Board of Scientific Advisors/NCAB virtual meeting, February 2023 virtual meeting, March 2023 virtual meeting, NIAAA/NIDA/NCAB May 2023 hybrid meeting, and June 2023 Joint NCI BSA/NCAB in-person/hybrid meeting were approved by the Board members during fiscal year 2023.

20b. How does the Committee balance its membership?

The Board will consist of not more than 18 members appointed by the President (appointed members) and 12 nonvoting ex officio members. The nonvoting ex officio members will include the Secretary; the Director of the Office of Science and Technology Policy; the Director, NIH; the Under Secretary for Health of the Department of Veterans Affairs; the Director of the National Institute for Occupational Safety and Health; the Director of the National Institute of Environmental Health Sciences; the Secretary of Labor; the Commissioner of the Food and Drug Administration; the Administrator of the Environmental Protection Agency; the Chairman of the Consumer Product Safety Commission; the Assistant Secretary of Defense for Health Affairs;

and the Director of the Office of Energy Research of the Department of Energy (or their designees). All appointed members must be eligible to serve as Special Government Employees (SGEs) and will serve as SGEs. Two-thirds of the appointed members will be selected from among the leading representatives of the health and scientific disciplines (including not less than 2 individuals who are leaders in the fields of public health and the behavioral or social sciences) relevant to the activities of NCI. One-third of the appointed members will be representatives from the general public, including leaders in fields of public policy, law, health policy, economics and management. Not less than five of the appointed members will be individuals knowledgeable in environmental carcinogenesis (including carcinogenesis involving occupational and dietary factors). Not less than one member shall be an individual knowledgeable in pediatric oncology.

20c. How frequent and relevant are the Committee Meetings?

As mandated, meetings are held not less than four times a year. The committee met six times during this reporting period. The Board met jointly with NIAAA/NIDA on 10 May 2023 in-person/hybrid and jointly with the NCI Board of Scientific Advisors for the December 2023 virtual and June 2023 in-person/hybrid meetings. The Board also met virtually at the February 2023, March 2023, and September 2023 meetings. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing scientific programs. The Ad Hoc Subcommittee on

Global Cancer Research; the Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities; and the Subcommittee on Clinical Investigations met on 5 December 2022. The Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities and the Planning and Budget Subcommittee met on 9 February 2023. The Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities met on 13 June 2023. The NCAB Ad Hoc Working Group on Strategic Approaches and Opportunities for Research on Cancer Among Racial and Ethnic Minorities and Underserved Populations met virtually on 13 October 2022 and 22 November 2022.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The NCAB provides second level of peer review and advises on policy development; program implementation, and evaluation; and identifies research needs and opportunities of the Institute. The quality, scope, and balance of advice from this Board cannot be obtained from NIH staff or from other established sources as membership of the Board is constituted to meet specific requirements of the mandated mission of the Board and of the NCI.

20e. Why is it necessary to close and/or partially closed committee meetings?

The meetings of the NCAB were partially closed to the public for the review of grant applications. Sections 552b(c)(4) and 552b(c)(6) of the Government in the Sunshine Act permit the closing of meetings where discussion of applications could reveal confidential trade secrets or commercial property such as patentable material and personal information, disclosure of

which would constitute a clearly unwarranted invasion of personal privacy.

21. Remarks

Committee Function: Other - National Scientific and Advisory. Max Number of Members Total: The Charter allows the Committee to have 18 authorized members included but not limited to SGEs and 12 Ex-Officios. There are 8 Alternates to Ex-Officios (Drs. Aubrey Miller, Joseph Graber, John Gordon, Michael Kelley, Richard Pazdur, Tara Schwetz, Craig Shriver, and Kerry Souza), a total of 26, which is four less than the Max number of members. Members Rotating Off/On-Boarding: Six members rotated-off (Drs. Francis Ali-Osman, Lawrence Gostin, Scott Hiebert, Electra Paskett, Nancy Raab-Traub and Margaret Spitz), one Ex Officio Member retired (Dr. Michael Babich), and six members were on-boarded (Ms. Margaret Anderson, Dr. Richard Boxer, Ms. Ysabel Duron, Ms. Julie Papanek Grant, Dr. Ana Navas-Acien, and Dr. Fred Tabung). This is why the charter states 30 potential members, but this ACR lists 32. Members: The terms of service for Drs. Francis Ali-Osman, Lawrence Gostin, Scott Hiebert, Electra Paskett, Nancy Raab-Traub and Margaret Spitz have changed due to administrative extensions. As such, their term end dates are different than what was reported on the FY22 ACR. The term of service end date for Dr. Ashani Weeraratna has changed, it was inadvertently reported with an incorrect date on the FY22 ACR. The terms for Drs. Francis Ali-Osman, Lawrence Gostin, Scott Hiebert, Electra Paskett, Nancy Raab-Traub, and Margaret Spitz are longer than the charter allows due to delays in the appointment of new members and to ensure appropriate expertise was available for the mandatory second level of peer review. Ex Officio

Members: The term of service for Dr. Michael Babich changed due to retirement. He left the board on 2/28/2023. As such, his term of service end date is different than what was reported on the FY22 ACR. The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute. Reports: The working group report was deliberated on by the National Cancer Advisory Board.

Designated Federal Officer

PAULETTE S. GRAY DIRECTOR, DIVISION OF
EXTRAMURAL ACTIVITIES, NCI

Committee Members	Start	End	Occupation	Member Designation
ALI-OSMAN, FRANCIS	11/27/2016	08/26/2023	MARGARET HARRIS & DAVID SILVERMAN DISTINGUISHED PROFESSOR OF NEURO-ONCOLOGY RESEARCH, DUKE UNIVERSITY MEDICAL CENER	Special Government Employee (SGE) Member
ANDERSON, MARGARET	08/27/2023	03/09/2028	MANAGER DIRECTOR, DELOITTE CONSULTING LLP	Special Government Employee (SGE) Member
AZAD, NILOFER	01/30/2022	03/09/2026	PROFESSOR OF ONCOLOGY, CO-DIRECTOR, DEVELOPMENTAL THERAPEUTICS PROGRAM, CO-LEADER, CANCER GENETICS AND EPIGENETICS SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER, JOHNS HOPKINS UNIVERSITY	Special Government Employee (SGE) Member
BABICH, MICHAEL	12/04/2000	02/28/2023	DIRECTORATE FOR EPIDEMIOLOGY AND HEALTH SCIENCES, U.S. CONSUMER PRODUCT SAFETY COMMISSION	Ex Officio Member

BARKER, ANNA	05/26/2020	03/09/2024	CHIEF STRATEGY OFFICER, ELLISON INSTITUTE FOR TRANSFORMATIVE MEDICINE, UNIVERSITY OF SOUTHERN CALIFORNIA	Special Government Employee Member
BOXER, RICHARD	08/27/2023	03/09/2028	CLINICAL PROFESSOR, DEPARTMENT OF UROLOGY, DAVID Geffen School of Medicine, University of California, Los Angeles	Special Government Employee Member
CARPEN, JOHN	12/05/2021	03/09/2026	DIRECTOR, COMPREHENSIVE CANCER CENTER, DIRECTOR AND CHIEF SCIENCE OFFICER, BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE	Special Government Employee (SGE) Member
DIAZ, LUIS	07/31/2022	03/09/2024	HEAD, DIVISION OF SOLID TUMOR ONCOLOGY, GRAY FAMILY CHAIR IN MEDICINE, DEPARTMENT OF MEDICINE, MEMORIAL SLOAN KETTERING CANCER CENTER	Special Government Employee (SGE) Member
DURON, YSABEL	08/27/2023	03/09/2028	FOUNDER AND EXECUTIVE DIRECTOR, THE LATINO CANCER INSTITUTE	Special Government Employee (SGE) Member
FINGERT, HOWARD	05/26/2020	03/09/2024	VICE PRESIDENT, MEDICAL-ONCOLOGY, ONO PHARMA USA, INC.	Special Government Employee (SGE) Member

FRIESE, CHRISTOPHER	01/30/2022	03/09/2026	<p>ELIZABETH TONE HOSMER PROFESSOR OF NURSING, DIRECTOR, CENTER FOR IMPROVING PATIENT AND POPULATION SCIENCES, ASSOCIATE DIRECTOR FOR CANCER CONTROL AND POPULATION SCIENCES, UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER, UNIVERSITY OF MICHIGAN DIRECTOR FOR HEALTH SCIENCES, U.S. CONSUMER PRODUCT SAFETY COMMISSION UNIVERSITY PROFESSOR, FACULTY DIRECTOR, AND FOUNDING LINDA D. AND TIMOTHY J. O'NEILL PROFESSOR IN GLOBAL HEALTH LAW, GEORGETOWN UNIVERSITY SENIOR TECHNICAL ADVISOR, OFFICE OF BIOLOGICAL AND ENVIRONMENTAL RESEARCH, U.S. DEPARTMENT OF ENERGY</p>	<p>Special Government Employee (SGE) Member</p>
GORDON, JOHN	03/01/2023	12/31/2028	<p>U.S. CONSUMER PRODUCT SAFETY COMMISSION UNIVERSITY PROFESSOR, FACULTY DIRECTOR, AND FOUNDING LINDA D. AND TIMOTHY J. O'NEILL PROFESSOR IN GLOBAL HEALTH LAW, GEORGETOWN UNIVERSITY SENIOR TECHNICAL ADVISOR, OFFICE OF BIOLOGICAL AND ENVIRONMENTAL RESEARCH, U.S. DEPARTMENT OF ENERGY</p>	<p>Ex Officio Member</p>
GOSTIN, LAWRENCE	11/27/2016	08/26/2023	<p>U.S. CONSUMER PRODUCT SAFETY COMMISSION UNIVERSITY PROFESSOR, FACULTY DIRECTOR, AND FOUNDING LINDA D. AND TIMOTHY J. O'NEILL PROFESSOR IN GLOBAL HEALTH LAW, GEORGETOWN UNIVERSITY SENIOR TECHNICAL ADVISOR, OFFICE OF BIOLOGICAL AND ENVIRONMENTAL RESEARCH, U.S. DEPARTMENT OF ENERGY</p>	<p>Special Government Employee (SGE) Member</p>
GRABER, JOSEPH	11/12/2020	12/31/2025	<p>U.S. CONSUMER PRODUCT SAFETY COMMISSION UNIVERSITY PROFESSOR, FACULTY DIRECTOR, AND FOUNDING LINDA D. AND TIMOTHY J. O'NEILL PROFESSOR IN GLOBAL HEALTH LAW, GEORGETOWN UNIVERSITY SENIOR TECHNICAL ADVISOR, OFFICE OF BIOLOGICAL AND ENVIRONMENTAL RESEARCH, U.S. DEPARTMENT OF ENERGY</p>	<p>Ex Officio Member</p>
GRANT, JULIE	09/24/2023	03/09/2028	<p>GENERAL PARTNER, CANANN</p>	<p>Special Government Employee (SGE) Member</p>
HAYES-DIXON, ANDREA	05/26/2020	03/09/2024	<p>DEAN, HOWARD UNIVERSITY COLLEGE OF MEDICINE, VICE PRESIDENT OF CLINICAL AFFAIRS, CHAIR OF SURGERY, HOWARD UNIVERSITY HOSPITAL</p>	<p>Special Government Employee (SGE) Member</p>

HEIMBERGER, AMY	01/30/2022	03/09/2026	JEAN MALNATI MILLER PROFESSOR OF BRAIN TUMOR RESEARCH, VICE CHAIR FOR RESEARCH, DEPARTMENT OF NEUROSURGERY, NORTHWESTERN UNIVERSITY, FEINBERG SCHOOL OF MEDICINE HORTENSE B. INGRAM CHAIR IN CANCER RESEARCH, PROFESSOR OF BIOCHEMISTRY DEPARTMENT OF BIOCHEMISTRY VANDERBILT UNIVERSITY SCHOOL OF MEDICINE NATIONAL PROGRAM DIRECTOR FOR ONCOLOGY, U.S. DEPARTMENT OF VETERAN AFFAIRS	Special Government Employee (SGE) Member
HIEBERT, SCOTT	11/27/2016	08/26/2023	CHIEF EXECUTIVE OFFICER AND MEDICAL DIRECTOR AHURA HEALTHCARE CORPORATION SENIOR MEDICAL ADVISOR, NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES, NATIONAL INSTITUTES OF HEALTH PROFESSOR OF ENVIORNMENTAL HEALTH SCIENCES, DEPARTMENT OF ENVIORNMENTAL HEALTH SCIENCES, MAILMAN SCHOOL OF PUBLIC HEALTH, COLUMBIA UNIVERSITY	Special Government Employee (SGE) Member
KELLEY, MICHAEL	02/04/2008	12/31/2025		Ex Officio Member
KHATIBI, NIKAN	10/25/2020	03/09/2024		Special Government Employee (SGE) Member
MILLER, AUBREY	06/09/2011	12/31/2023		Ex Officio Member
NAVAS-ACIEN, ANA	08/27/2023	03/09/2028		Special Government Employee (SGE) Member

PASKETT, ELECTRA	11/27/2016	08/26/2023	MARION N. ROWLEY PROFESSOR OF CANCER RESEARCH, DIRECTOR, DIVISION OF CANCER PREVENTION AND CONTROL, DEPARTMENT OF INTERNAL MEDICINE, COLLEGE OF MEDICINE, THE OHIO STATE UNIVERSITY DIRECTOR, ONCOLOGY CENTER OF EXCELLENCE, U.S. FOOD AND DRUG ADMINISTRATION	Special Government Employee (SGE) Member
PAZDUR, RICHARD	09/01/2002	12/31/2025	PROFESSOR, DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY, LINEBERGER COMPREHENSIVE CANCER CENTER, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	Ex Officio Member
RAAB-TRAUB, NANCY	11/27/2016	08/26/2023	DIRECTOR, JOHN P. MURTHA CANCER CENTER, U.S. DEPARTMENT OF DEFENSE EPIDEMIOLOGIST, NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH	Special Government Employee (SGE) Member
SHRIVER, CRAIG	08/22/2012	12/31/2023	PROFESSOR EMERITUS, DEPARTMENT OF MEDICINE, DAN L. DUNCAN CANCER CENTER, BAYLOR COLLEGE OF MEDICINE	Ex Officio Member
SOUZA, KERRY	04/30/2013	12/31/2025	ASSISTANT PROFESSOR, DEPARTMENT OF INTERNAL MEDICINE, COLLEGE OF MEDICINE AND COMPREHENSIVE CANCER CENTER, THE OHIO STATE UNIVERSITY	Ex Officio Member
SPITZ, MARGARET	11/27/2016	08/26/2023		Special Government Employee (SGE) Member
TABUNG, FRED	08/27/2023	03/09/2028		Special Government Employee (SGE) Member

NAME	DATE OF BIRTH	DATE OF DEATH	EDUCATION	PROFESSION
VADAPARAMPIL, SUSAN	05/26/2020	03/09/2024	ASSOCIATE CENTER DIRECTOR COMMUNITY OUTREACH, ENGAGEMENT, AND EQUITY PROFESSOR DEPARTMENT OF HEALTH OUTCOMES AND BEHAVIOR MOFFITT CANCER CENTER BLOOMBERG DISTINGUISHED PROFESSOR OF CANCER BIOLOGY, E.V. MCCOLLUM CHAIR OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH, JOHNS HOPKINS UNIVERSITY	Special Government Employee (SGE) Member
WEERARATNA, ASHANI	01/30/2022	03/09/2026	EXECUTIVE DIRECTOR MEHARRY-VANDERBILT ALLIANCE INGRAM PROFESSOR OF CANCER RESEARCH PROFESSOR OF RADIATION ONCOLOGY VANDERBILT UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
WINKFIELD, KAREN	01/30/2022	03/09/2026		

Number of Committee Members Listed: 32

Narrative Description

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. NCI works to fulfill that mission with the support of the National Cancer Advisory Board (NCAB), which is composed of both scientific and public members, and provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative

agreements, where direct costs per annum exceed \$50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). During the year, the NCAB was presented reports on various topics related to cancer research in general, and the operational aspects of the Institute's intramural and extramural programs. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing research programs.

What are the most significant program outcomes associated with this committee?

	Checked if Applies
Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input checked="" type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input checked="" type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Outcome Comments

The NCAB continues to be instrumental in monitoring the development and execution of the activities of the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. In 2023, NCI used its resources to support the best science and ensure continued advances with a focus on the eight goals of the National Cancer Plan which include the following: preventing cancer; detecting cancer early; developing effective treatments; eliminating inequities; delivering optimal care; engaging every person; maximizing data utility; and optimizing the workforce. There were also well-reasoned discussions regarding the NCI's Childhood

Cancer Data Initiative; Status of the Advance Research Projects Agency for Health (ARPA-H); Future Directions for the Division of Cancer Control and Population Sciences; Multiple Myeloma and Disparities; Adapting NCI's Clinical Trials System to a Changed Clinical Research Environment; National Cancer Plan; Cancer Research Collaborations with the European Union; Progress in Targeting KRAS through the Frederick RAS Initiative; NCI Budget; and Collaborative Approaches to Accelerate Better Therapies for Patients with Rare Tumors. Additionally, the Board deliberated and accepted the Report of the NCAB ad hoc Working Group on Strategic Approaches and Opportunities for Research on Cancer Among Racial and Ethnic Minorities and Underserved Populations.

What are the cost savings associated with this committee?

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

264

Number of Recommendations Comments

In addition to some general recommendations, in FY 2023, some specific committee recommendations included the following: A motion to accept the Report of the NCAB ad hoc Working Group on Strategic Approaches and Opportunities for Research on Cancer Among Racial and Ethnic Minorities and Underserved Populations was approved unanimously. A motion to accept the report of the 5 December 2022 NCAB ad hoc Global Cancer Research Subcommittee meeting was approved unanimously. A motion to accept the report of the 5 December 2022 NCAB ad hoc Population Science, Epidemiology, and Disparities Subcommittee meeting was approved unanimously. A motion to accept the

report of the 5 December 2022 NCAB Clinical Investigations Subcommittee meeting was approved unanimously. A motion to approve the NCI Annual Delegations of Authority was approved unanimously. A motion to accept the report of the 9 February 2023 NCAB ad hoc Subcommittee on Population Science, Epidemiology, and Disparities meeting was approved unanimously. A motion to accept the report of the 9 February 2023 NCAB Subcommittee on Planning and Budget meeting was approved unanimously. A motion to concur with establishing an NCAB ad hoc Review Group for the Evaluation of the Scientific Directors in the NCI Center for Cancer Research was approved unanimously. A motion to accept the NCI National Cancer Plan was approved unanimously. A motion to accept the report of the 13 June 2023 NCAB ad hoc Population Science, Epidemiology, and Disparities Subcommittee meeting was approved unanimously. A motion to concur with establishing an NCAB Working Group on Workforce and Training in Population Science was approved unanimously.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

0%

% of Recommendations Fully Implemented Comments

Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

0%

% of Recommendations Partially Implemented Comments

Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

Does the agency provide the committee with feedback regarding actions taken to

implement recommendations or advice offered?Yes ☒ No ☐ Not Applicable ☐**Agency Feedback Comments**

Information is provided to the public at the open session of each Board meeting through reports and the Director's update. The public can view information related to the Board through the NCAB's official website.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input checked="" type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Action Comments

An action of approved or recommended for grants receiving review by this Board does not infer that the grant will be or has been funded. Research grant applications submitted to NIH must go through a two-step review process that includes the initial peer review for scientific and technical merit and a second step of review and approval by the National Advisory Council that includes program relevance. In addition, prior to an award or funding being made, NIH staff must conduct an administrative review for a number of other considerations. These include alignment with NIH's funding principles, review of the project budget, assessment of the applicant's management systems, determination of applicant eligibility, and compliance with public policy requirements. After all these steps, have been completed, NIH officials make funding decisions on individual grant applications. NCI used its resources to support the best science and ensure continued advances with a focus on the eight goals of the National Cancer Plan which include the following: preventing cancer; detecting cancer early; developing effective treatments; eliminating inequities; delivering optimal care; engaging every person; maximizing data utility; and optimizing the workforce. There were also well-reasoned discussions regarding the NCI's Childhood Cancer Data Initiative; Status of the Advance Research Projects Agency for Health (ARPA-H); Future Directions for the Division of Cancer Control and Population Sciences; Multiple Myeloma and Disparities; Adapting NCI's Clinical Trials System to a Changed Clinical Research Environment; National Cancer Plan; Cancer Research Collaborations with the European Union; Progress in Targeting KRAS through

the Frederick RAS Initiative; NCI Budget; and Collaborative Approaches to Accelerate Better Therapies for Patients with Rare Tumors.

Is the Committee engaged in the review of applications for grants?

Yes

What is the estimated Number of grants reviewed for approval

What is the estimated Number of grants recommended for approval 13,567
13,567

What is the estimated Dollar Value of grants recommended for approval
\$5,341,641,008

Grant Review Comments

The number of grants reviewed/recommended and dollar value includes NCI grants and FDA SBIR grants.

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Access Comments

Information on the NCAB can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at <https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm>. Each NCI committee's charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint Presentations and reports is located here. Additionally, the public may view the NCAB meetings (both live and on demand) via the NIH Videocast at the following website: <http://videocast.nih.gov/>.